Spots Global Cancer Trial Database for SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer

Official Title: Cytogenetic and Flow Cytometric Analysis of : Renal Cell Carcinoma: A Companion Protocol to SWOG-8949

Study ID: NCT00900042

Conditions

Kidney Cancer

Interventions

DNA ploidy analysis

DNA stability analysis

chromosomal translocation analysis

cytogenetic analysis

flow cytometry

laboratory biomarker analysis

Study Description

Brief Summary: RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer.

Detailed Description: OBJECTIVES: * Determine if cytogenetic abnormalities can predict clinical outcome, in terms of response to treatment and survival, in patients with metastatic renal cell carcinoma registered to the nephrectomy arm (arm I) of SWOG-8949. * Correlate cytogenetic abnormalities and DNA content analysis (DNA index and S-phase fraction) with clinical outcome. OUTLINE: This is a partially prospective, partially retrospective, multicenter, companion study. Paraffin-embedded tumor tissue specimens from patients enrolled in SWOG-8949 are evaluated by cytogenetic analysis (e.g., presence of trisomy and loss of Y chromosome) and flow cytometric analysis (e.g., presence of nondiploid cells and presence of abnormal proliferation index). PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.